Metabolische Chirurgie

ZUSAMMENFASSUNG

Die metabolische Chirurgie ist aktuell die effektivste Therapie zur Behandlung der morbiden Adipositas und der assoziierten Begleiterkrankungen. Der Beitrag stellt die Operationsverfahren und deren Stellenwert vor.

Publication History

Article published online:
03 August 2023

• Literatur

• 1 Hung S, Chen C, Chin W. et al The long-term risk of cardiovascular events in patients following bariatric surgery compared to a non-surgical population with obesity and the general population: a comprehensive national cohort study. Langenbeckʼs Arch Surg 2021; 406: 189-196
• 2 Carlsson L, Sjöholm K, Jacobson P. et al Life expectancy after bariatric surgery in the Swedish Obese Subject Study. N Engl J Med 2020; 383: 1535
• 3 Schauer PR, Bhatt DL, Kirwan JP. et al Bariatric surgery versus intensive medical therapy for diabetes–5-year outcomes. N Engl J Med 2017; 376: 641-651
• 4 Rubino F, Nathan DM, Eckel RH. et al Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by International Diabetes Organizations. Diabetes Care 2016; 39: 861-877
• 5 Adams LA, Waters OR, Knuiman MW. et al NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104: 861-867
• 6 Colquitt JL, Pickett K, Loveman E. et al Surgery for weight loss in adults. Cochrane Database Syst Rev 2014; 08: CD003641
• 7 Yan Y, Sha Y, Yao G. et al Roux-en-Y gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients: a systematic review and meta-analysis of randomized controlled trials. Medicine 2016; 95: e3462
• 8 Deutsche Adipositas-Gesellschaft e.V. (DAG), et al. S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen. 2018. Version 2.3. AWMF-Register Nr. 088–001. Im Internet (Stand: 16.06.2022) https://www.awmf.org/uploads/tx_szleitlinien/088-001l_S3_Chirurgie-Adipositas-metabolische-Erkrankugen_2018-02.pdf
• 9 Aminian A, Al-Kurd A, Wilson R. et al Association of Bariatric Surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 2021; 326: 2031-2042
• 10 Lassailly G, Caiazzo R, Ntandja-Wandji LC. et al Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 2020; 159: 1290-1301.e5
• 11 Stroh C, Hohmann U, Manger T. Prinzipien der Adipositaschirurgie. Internist Prax 2015; 55: 737-746
• 12 Thaher O, Hukauf M, Stroh C. Propensity score matching sleeve gastrectomy vs. gastric bypass with 5 years of followup. Obes Surg 2021; 31: 5156-5165
• 13 Peterli R, Wolnerhanssen BK, Peters T. et al Effect of laparoscopic sleeve gastrectomy vs. laparoscopic roux-en-y-gastric bypass on weight loss in patients with morbid obesity: The SM-BOSS Randomized Clinical Trial. JAMA 2018; 319: 255-265
• 14 Mingrone G, Panunzi S, De Gaetano A. et al Bariatric surgery versus conventional therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-1585
• 15 Mingrone G, Panunzi S, de Gaetano A. et al Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow up on an open-label, single-centre, randomised controlled trial. Lancet 2015; 386: 964-973
• 16 Salminen P, Helmiö M, Ovaska J. et al Effect of laparoscopic sleeve gastrectomy vs. laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity. The SLEEVEPASS randomized clinical trial. JAMA 2018; 319: 241-254
• 17 Wölnerhanssen B, Peterli R, Hurme S.. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy: 5-year outcomes of merged data from two randomized clinical trials (SLEEVEPASS and SM-BOSS). Br J Surg 2021; 108: 49-57
• 18 Robert M, Espalieu P, Pelascini E. et al Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomized, openlabel, non-inferiority trial. Lancet 2019; 393: 1299-1309
• 19 Sjöström L, Lindroos A, Peltonen P. et al Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693
• 20 Biertho L, Lebel S, Marceau S. et al Biliopancreatic diversion with duodenal switch: Surgical Technique and operative care. Surg Clin North Am 2016; 96: 815-826
• 21 Bueter M, le Roux CW. Gastrointestinal hormones, energy balance and bariatric surgery. Int J Obes (Lond) 2011; 35 (Suppl. 03) S35-S39
• 22 Buhmann H, le Roux CW, Bueter M. The gut-brain axis in obesity. Best Pract Res Clin Gastroenterol 2014; 28: 559-571
• 23 Moreno-Arciniegas A, Falckenheiner-Soria J, Bancalero-De-Los Reyes J. et al The main participation of the enterohormone GLP-1 after bariatric surgery. Minerva Chir 2019; 74: 7-13
• 24 Steinert RE, Feinle-Bisset C, Asarian L. et al Ghrelin, CCK, GLP-1, and PYY (3-36): Secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 2017; 97: 411-463
• 25 Steinert RE, Rehman A, Souto Lima EJ. et al Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients – a pilot study. PloS One 2020; 15: e0236936
• 26 Albaugh VL, Banan B, Antoun J. et al Role of bile acids and GLP-1 in mediating the metabolic improvements of bariatric surgery. Gastroenterology 2019; 156: 1041-1051.e4
• 27 Bozadjieva N, Heppner K, Seeley R. Targeting FXR and FGF19 to treat metabolic diseases – lessons learned from bariatric surgery. Diabetes 2018; 67: 1720
• 28 Debedat J, Sokovska N, Couzpaye M. et al Long-termrelapse of type 2 diabetes after Roux-en-Y gastric bypass: prediction and clinical relevance. Diabetes Care 2018; 41: 2086-2095
• 29 Thereux J, Lesuffleur T, Czernichow S. et al Association between bariatric surgery and rates of continuation, discontinuation, or initiation of antidiabetes treatment 6 years later. JAMA Surg 2018; 153: 526-533
• 30 Fischer D, Johnson E, Hanreuse S. et al Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA 2018; 320: 1570-1582
• 31 OʼBrien R, Johnson E, Haneuse S. et al Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care. Ann Int Med 2018; 169: 300-310
• 32 Billeter A, Scheurlen K, Probst P. et al Meta-analysis of metabolic surgery versus medical treatment for microvascular complications in patients with type 2 diabetes mellitus. Br J Surg 2018; 105: 168-181
• 33 Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 2008; 34: 634-637
• 34 Schauer DP, Feigelson HS, Koebnick C. et al Bariatric surgery and the risk of cancer in a large multisite cohort. Ann Surg 2019; 269: 95-101
• 35 Feigelson HS, Caan B, Weinmann S. et al Bariatric Surgery is associated with reduced risk of breast cancer in both premenopausal and postmenopausal women. Ann Surg 2020; 272: 1053-1059
• 36 Bailly L, Fabre R, Pradier C. et al Colorectal cancer risk following bariatric surgery in a nationwide study of French individuals with obesity. JAMA Surg 2020; 155: 395-402
• 37 Hussan H, Patel A, Le Roux M. et al Rising incidence of colorectal cancer in young adults corresponds with increasing surgical resections in obese patients. Clin Transl Gastroenterol 2020; 11: e00160
• 38 Stroh C, Meyer F, Manger T. Nutritive Defizite und Supplementation nach metabolischer Chirurgie. Chirurg 2016; 87: 762-767
• 39 Almeanazel O, Alanazi F, Alsarra I. et al Nanotechnology as a tool to overcome the bariatric surgery malabsorption. Saudi Pharm J 2020; 28: 565-573
• 40 Anvari S, Lee Y, Lam M. et al The effect of bariatric surgery on oral antibiotic absorption: a systematic review. Obes Surg 2020; 30: 2883-2892
• 41 Carlsson LMS, Sjöholm K, Jacobson P. et al Life Expectancy after bariatric surgery in the Swedish Obese Subjects Study. N Engl J Med 2020; 383: 1535-1543
• 42 Stroh C, Croner R. 16. Studientreffen des GBSR. CHAZ 2020; 10: 537-539